The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients

Transplantation

Volumn 61, Issue 6, 1996, Pages 875-880

  Barone, Gary ^a   Chang, Cheng Tao ^b   Choc Jr , M Gerry ^b   Klein, Jon B ^c   Marsh, Christopher L ^d   Meligeni, John A ^b   Min, David I ^e   Pescovitz, Mark D ^f   Pollak, Raymond ^g   Pruett, Timothy L ^h   Stinson, James B ⁱ   Thompson, John S ^j   Vasquez, Eva ^g   Waid, Thomas ^j   Wombolt, Duane G ^k   Wong, Robert L ^b  

^a UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^b Sandoz Pharma Ltd   (Switzerland)

^c University of Louisville School of Medicine   (United States)

^d UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^e UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^f INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^h UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

ⁱ Latter Day Saints Hospital   (United States)

^j UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^k EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERANCE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CREATININE; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EMULSIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDIVIDUALITY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 9244244130     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199603270-00005     Document Type: Article

References (23)

1. Lindholm A. Therapeutic monitoring of cyclosporin: an update. Eur J Clin Pharmacol 1991; 41: 273.
2. Ptachcinski RJ, Venkataramanan R, Burckart GJ. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet 1986; 11: 107.
3. Rodighiero V. Therapeutic drug monitoring of cyclosporin: practical applications and limitations. Clin Pharmacokinet 1989; 16: 27.
4. Ohlman S, Lindholm A, Hägglund H, Säive J, Kahan BD. On the intraindividual variability and chronobiology of cyclosporine pharmacokinetics in renal transplantation. Eur J Clin Pharmacol 1993; 44: 265.
5. Bowers LD, Canafax DM, Singh J, Seifedlin R, Simmons RL, Najarian JS. Studies of cyclosporine blood levels: analysis, clinical utility, pharmacokinetics, metabolites, and chronopharmacology. Transplant Proc 1986; 18(suppl 5): 137.
6. Honcharik N, Yatscoff RW, Jeffery JR, Rush DN. The effect of meal composition on cyclosporine absorption. Transplantation 1991; 52: 1087.
7. Lindholm A. Factors influencing the pharmacokinetics of cyclosporine in man. Ther Drug Monit 1991; 13: 465.
8. Ptachcinski RJ, Venkataramanan R, Rosenthal JT, Burckart GJ, Taylor RJ, Hakala TR. The effect of food on cyclosporine absorption. Transplantation 1985; 40: 174.
9. Vonderscher J, Meinzer A. Rationale for the development of Sandimmune Neoral. Transplant Proc 1994; 26: 2925.
10. Kovarik JM, Mueller EA, van Bree JB, Tetzloff W, Kutz K. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci 1994; 83: 444.
11. Shaw LM, Bowers L, Demers L, et al. Critical issues in cyclosporine monitoring: report of the task force on cyclosporine monitoring report. Clin Chem 1987; 33: 1269.
12. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993; 54: 205.
13. Schroeder TJ, Hariharan S, First MR. Relationship between cyclosporine bioavailability and clinical outcome in renal transplant recipients. Transplant Proc 1994; 26: 2787.
14. Mehta MU, Venkataramanan R, Burckart GJ, et al. Effect of bile on cyclosporin absorption in liver transplant patients. Br J Clin Pharmacol 1988; 25: 579.
15. Shriner DA, Yee GC, Salomon DR, et al. Influence of dietary fat and bile salts on oral cyclosporine absorption in renal transplant patients (Abstract 88) Pharmacotherapy 1991; 11: 277.
16. Mueller EA, Kovarik JM, van Bree JB, Lison AE, Kutz K. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients - a concentration-controlled comparison with the commercial formulation. Transplantation 1994; 57: 1178.
17. Kovarik JM, Mueller EA, van Bree JB, Arns W, Renner E, Kutz K. Within-day consistency in cyclosporine pharmacokinetics from a microemulsion formulation in renal transplant patients. Ther Drug Monit 1994; 16: 232.
18. Kahan BD, Dunn J, Fitts C, et al. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation 1995; 59: 505.
19. Kahan BD, Dunn J, Fitts C, et al. The Neoral formulation: improved correlation between cyclosporine trough levels and exposure in stable renal transplant recipients. Transplant Proc 1994; 26: 2940.
20. Dunn OJ, Clark V. Correlation coefficients measured on the same individuals. J Am Stat Assoc 1969; 64: 366.
21. Holt DW, Mueller EA, Kovarik JM, van Bree JB, Kutz K. The pharmacokinetics of Sandimmun Neoral: a new oral formulation of cyclosporine. Transplant Proc 1994; 26: 2935.
22. Kasiske BL, Heim-Duthoy K, Rao KV, Awni WM. The relationship between cyclosporine pharmacokinetic parameters and subsequent acute rejection in renal transplant recipients. Transplantation 1988; 46: 716.
23. Mueller EA, Kovarik JM, van Bree JB, Tezloff W, Grevel J, Kutz K. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res 1994; 11: 301.